This HTML5 document contains 34 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n2http://linked.opendata.cz/resource/drugbank/drug/
dctermshttp://purl.org/dc/terms/
foafhttp://xmlns.com/foaf/0.1/
n17http://linked.opendata.cz/resource/drugbank/dosage/
n9http://linked.opendata.cz/resource/drugbank/drug/DB05332/identifier/kegg-drug/
n7http://linked.opendata.cz/resource/drugbank/drug/DB05332/identifier/drugbank/
n14http://www.rxlist.com/
n11http://bio2rdf.org/drugbank:
n5http://linked.opendata.cz/resource/drugbank/drug/DB05332/identifier/national-drug-code-directory/
admshttp://www.w3.org/ns/adms#
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
owlhttp://www.w3.org/2002/07/owl#
n3http://linked.opendata.cz/ontology/drugbank/
n13http://www.drugs.com/monograph/
n18http://linked.opendata.cz/resource/drugbank/property/
xsdhhttp://www.w3.org/2001/XMLSchema#
n6http://linked.opendata.cz/resource/drugbank/drug/DB05332/identifier/wikipedia/
n16http://linked.opendata.cz/resource/atc/
n15http://linked.opendata.cz/ontology/sukl/drug/

Statements

Subject Item
n2:DB05332
rdf:type
n3:Drug
n3:description
Romiplostim is a thrombopoiesis stimulating dimer Fc-peptide fusion protein (peptibody) to increase platelet production through activation of the thrombopoietin receptor. The peptibody molecule has two identical single-chain subunits, each one is made up of 269 amino acid residues. Each subunit consists of an IgG1 Fc carrier domain that is covalently attached to a polypeptide sequence that contains two binding domains to interact with thrombopoietin receptor c-Mpl. Each domain consists of 14 amino acids. Interestingly, romiplostim's amino acid sequence is not similar to that of endogenous thrombopoietin. Romiplostim is produced by recombinant DNA technology in Escherichia coli. FDA approved on August 22, 2008.
n3:dosage
n17:271B4139-363D-11E5-9242-09173F13E4C5 n17:271B413A-363D-11E5-9242-09173F13E4C5 n17:271B413B-363D-11E5-9242-09173F13E4C5 n17:271B413C-363D-11E5-9242-09173F13E4C5
n3:generalReferences
# Kumagai Y, Fujita T, Ozaki M, Sahashi K, Ohkura M, Ohtsu T, Arai Y, Sonehara Y, Nichol JL: Pharmacodynamics and Pharmacokinetics of AMG 531, a Thrombopoiesis-Stimulating Peptibody, in Healthy Japanese Subjects: A Randomized, Placebo-Controlled Study. J Clin Pharmacol. 2007 Dec;47(12):1489-97. Epub 2007 Oct 9. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/17925591 # Rice L: Drug evaluation: AMG-531 for the treatment of thrombocytopenias. Curr Opin Investig Drugs. 2006 Sep;7(9):834-41. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/17002262 # Keating GM: Romiplostim: a review of its use in immune thrombocytopenia. Drugs. 2012 Feb 12;72(3):415-35. doi: 10.2165/11208260-000000000-00000. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/22316355 # FDA label # http://www.google.com/patents/US6835809 # http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PALL&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.htm&r=1&f=G&l=50&s1=6835809.PN.&OS=PN/6835809&RS=PN/6835809
n3:group
approved
n3:halfLife
Immune thrombocytopenia patients, subQ = 3.5 days (median) (range 1-34 days)
n3:indication
Treatment of chronic immune thrombocytopenic purpura.
owl:sameAs
n11:DB05332
dcterms:title
Romiplostim
adms:identifier
n5:55513-221-01 n6:Romiplostim n7:DB05332 n9:D08990
n3:mechanismOfAction
Romiplostim is a thrombopoietin receptor agonist that activates intracellular transcriptional pathways via c-Mpl to increase production of platelets. It also works similarly to thrombopoietin (TPO), an endogenous glycoprotein hormone that regulates the production of platelets in the bone marrow.
n3:routeOfElimination
Renal clearance (more dominant mode of clearance as dose increases) and binding to c-Mpl receptors (dominant mode of clearance at low doses)
n3:synonym
Semaxinib SU-5416 SID50107014 SID49674962 Semaxanib
n3:toxicity
The most common adverse reactions (≥ 5% higher patient incidence in Nplate versus placebo) are arthralgia, dizziness, insomnia, myalgia, pain in extremity, abdominal pain, shoulder pain, dyspepsia, and paresthesia. Headache was the most commonly reported adverse reaction that did not occur at ≥ 5% higher patient incidence in Nplate versus placebo. LD50 = 980 mg/kg.
n3:volumeOfDistribution
In healthy volunteers, non-linear decrease in Vd with increase IV dose of romiplostim which indicates saturation of c-Mpl receptors. Vd, 0.3 μg/kg = 122 mL/kg Vd, 10 μg/kg = 48.2 mL/kg
foaf:page
n13:romiplostim.html n14:nplate-drug.htm
n3:Molecular-Formula
n18:271B413E-363D-11E5-9242-09173F13E4C5
n3:Molecular-Weight
n18:271B413D-363D-11E5-9242-09173F13E4C5
n15:hasATCCode
n16:B02BX04
n3:absorption
Cmax, healthy volunteers, subQ = 24-36 hours; Cmax, immune thrombocytopenia patients, subQ = 7-50 hours (median = 14 hours). Not affected by age, weight, or gender. Accumulation does not occur after six weekly doses of 3 mcg/kg romiplostim.
n3:affectedOrganism
Humans and other mammals
n3:casRegistryNumber
267639-76-9
n3:category